ERT's Scientific and Regulatory Consultants Support Phase III Oncology Trial
Provectus Biopharmaceuticals Collaborates with ERT's COA Experts to Understand Patient Perspective during Melanoma Drug Development
ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced that Provectus Biopharmaceuticals (NYSE MKT: PVCT) is collaborating with ERT’s Clinical Outcome Assessment (COA) consultants on their Phase III trial of agent PV-10 for intralesional (IL) treatment of locally advanced cutaneous melanoma.
PV-10, an investigational new drug designed for injection into solid tumors, has received orphan drug designation from the U.S. FDA for its melanoma and hepatocellular carcinoma indications. Provectus recently presented data from their Phase II trials showing PV-10’s ablative and bystander effects, including its potential to relieve symptoms of cutaneous melanoma.
“We are thrilled to collaborate with ERT’s scientific and regulatory experts on this important program,” said Eric Wachter, PhD and Chief Technology Officer of Provectus. “Their expertise in developing and evaluating symptom measures to support clinical trial endpoints will be instrumental in helping us understand the patients’ perspective as we continue to explore the therapeutic potential of PV-10.”
ERT’s COA consultants are working with Provectus to select a patient-reported outcome (PRO) measure of symptoms in this population that can be implemented in the Phase III clinical trial of PV-10 and ultimately support treatment benefit claims in the product label.
“Provectus is a true innovator in oncology clinical research,” said Dr. Chad Gwaltney, ERT’s Chief Scientist and Regulatory Advisor, Endpoints. “By applying scientific rigor to the implementation of established PRO measures, they are not only striving to meet regulatory guidelines, they are putting the patient at the heart of clinical research. We applaud Provectus for placing such importance on understanding the patient perspective in oncology drug development, and we are delighted to work with them on this program.”
For additional information on ERT’s scientific and regulatory consulting services, visit www.ert.com/consulting.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
